The Journal of Practical Medicine ›› 2021, Vol. 37 ›› Issue (22): 2908-2913.doi: 10.3969/j.issn.1006⁃5725.2021.22.016

• Clinical Research • Previous Articles     Next Articles

Clinical effect of hydromorphone and oxycodone in patient⁃controlled intravenous analgesia after thoraco⁃ scopic radical resection of lung cancer 

WEI Shunmin,SUN Xude.   

  1. Department of Anesthesiology,Tangdu hospi⁃ tal,Air Force Medical University,Xi′an 710038,China

  • Online:2021-11-25 Published:2021-11-25
  • Contact: SUN Xude E⁃mail:sunxude@fmmu.edu.cn

Abstract:

Objective To study the analgesic effect of hydromorphone and oxycodone on PCIA after thora⁃ coscopic lung cancer surgery. Methods 144 patients with lung cancer were divided into three groups. 60 cases wereincluded in hydromorphone group,while 39 cases and 45 caseswererespectivelyincluded in oxycodone group and sufentanil group. PCIA was performed. NRS and adverse reactions at 3,6,12,24,36 and 48 hours were recorded. Results There was significant difference in NRS score among the three groups(P < 0.05). Multiple comparisons:the analgesic effects of hydromorphone and oxycodone were statistically significant from sufentanil (P < 0.05),whilethere was no significant difference between hydromorphone and oxycodone(P > 0.05). Adverse reactions:there was no significant difference at 3,6,24,36 and 48 hours(P > 0.05);whilethere was significant difference in dizziness 12 hours after operation(P < 0.05). Inmultiple comparisons,the incidence of dizziness between HM and SF was statistically significant(P = 0.010 < 0.0125,Chi ⁃ square partition). Conclusion The multimodal analgesia of hydromorphone PCIA combined with TPVB and intravenous ketorolac tromethamine can provide comfortable treatment after lung cancer surgery.

Key words:

hydromorphone, oxycodone, postoperative analgesia, lung cancer